跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MET-3
首页
药物
MET-3
MET-3
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CRYSTAL OF COMPOUND AS C-MET KINASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF
EP 3766870 A4
申请人: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD
优先权: 2018
CN
EP
US
WO
7 件公开
Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
US 9266890 B2
申请人: GRAY NATHANAEL S
优先权: 2010
US
6 件公开
SALT OF DIOXANE QUINOLINE COMPOUND, CRYSTAL FORM THEREOF, PREPARATION METHODS THEREFOR AND USES THEREOF
EP 4596553 A4
申请人: BEIJING SCITECH MQ PHARMACEUTICALS LTD
优先权: 2022
CN
EP
US
WO
4 件公开
ANTI-HER3 AND ANTI-MET ANTIBODIES AND USES THEREOF
EP 4680648 A1
申请人: BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD
优先权: 2023
CN
EP
US
WO
4 件公开
WT1 modified peptide
US 8105604 B2
申请人: SUGIYAMA HARUO
优先权: 2001
CN
US
4 件公开
2-oxo-3-benzylbenzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumours
US 8071593 B2
申请人: SCHADT OLIVER
优先权: 2007
US
4 件公开
Pyrimido-diazepinone compounds and methods of treating disorders
US 9676792 B2
申请人: DANA FARBER CANCER INST INC
优先权: 2014
US
4 件公开
PEPTIDES
EP 4619412 A2
申请人: CAROCELL BIO LTD
优先权: 2022
EP
US
WO
3 件公开
Substituted pyrrolo[2,3-2]pyrimidines as protein kinase inhibitors
US 7968557 B2
申请人: NOVARTIS AG
优先权: 2005
CN
US
3 件公开
Bispecific Anti ErbB3 / Anti cMet Antibodies
US 2010256339 A1
申请人: BOSSENMAIER BIRGIT
优先权: 2009
CN
US
3 件公开
第 1 / 10 页
上一页
下一页
药物
反馈